Marker Thrptcs Rg

Marker Therapeutics, a Houston‑based clinical‑stage immuno‑oncology company, develops multi‑TAA T cell therapies for AML, myelodysplastic syndromes, lymphoma and pancreatic cancer, targeting non‑engineered tumor‑specific T cells.

Headquarters: United States (USA)

Marker Thrptcs Rg Logo
Company Profile
  • Employees: 5
  • HQ: Houston
Traded Instruments
+ Add Instrument 1
Symbol Name Type Exchange Currency ISIN Status Actions
MRKR Marker Thrptcs Rg
Cap: 0.0B
EQUITY NMS USD US57055L1070 Active
📈
Home Login